Immunogenicity of infliximab and adalimumab: What is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

Expert Opinion on Drug Safety

Volumn 15, Issue 1, 2016, Pages 43-52

  Murdaca, Giuseppe ^a   Spanò, Francesca ^a   Contatore, Miriam ^a   Guastalla, Andrea ^a   Penza, Elena ^a   Magnani, Ottavia ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

adalimumab; hypersensitivity reactions; immune mediated diseases; immunogenicity; infliximab

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; INJECTION SITE REACTION; REMISSION; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; IMMUNE SYSTEM DISEASES; IMMUNOLOGY;

ADALIMUMAB; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLIXIMAB; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84955182846     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1112375     Document Type: Review

References (93)

1. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009;22 (3):557-565.
2. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 2003;3:323-328.
3. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents-A guide for GPs. Aust Fam Physician. 2007;36:1035-1038.
4. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11 (1):1-5.
5. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11 (1):56-60.
6. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc). 2011;47 (4):277-288.
7. Puppo F, Murdaca G, Ghio M, et al. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev. 2005;4 (8):537-541.
8. Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin Drug Saf. 2013;12 (6):801-804.
9. Murdaca G, Spanò F, Puppo F. Long term treatment of rheumatoidarthritis with adalimumab. Open Access Rheum Res Rev. 2013;5:43-49.
10. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNFblocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819-836.
11. Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol. 2010;11 (6):437-439.
12. Murdaca G, Spanò F, Contatore M, et al. The potential use of TNF-α inhibitors in systemic sclerosis. Immunotherapy. 2014;6 (3):283-289.
13. Murdaca G, Spanò F, Contatore M, et al. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf. 2014;13 (5):649-661.
14. Murdaca G, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf. 2014;13 (3):295-305.
15. Launois R, Avouac B, Berenbaum F, et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: A multiple-treatment Bayesian metaanalysis. J Rheumatol. 2011;38 (5):835-845.
16. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell. 1994;76:959-962.
17. Murdaca G, Colombo BM, Contini P, et al. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res. 2012;32 (6):277-279.
18. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64 (Suppl 4):iv2-14.
19. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev. 2007;6:515-519.
20. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology. 2005;44:390-397.
21. Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med. 2011;6 (6):487-495.
22. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alphaexpressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15 (7):766-773.
23. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol. 2001;167:1072-1080.
24. Filaci G, Rizzi M, Setti M, et al. Nonantigen-specific CD8 (+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci. 2005;1050:115-123.
25. Ceeraz S, Hall C, Choy EH, et al. Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol. 2013;174 (1):18-26.
26. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: A model of vascular inflammation. Circulation. 2004;109 (14):1718-1723.
27. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224 (2):309-317.
28. Murdaca G, Spanò F, Cagnati P, et al. Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors. Redox Rep. 2013;18 (3):95-99.
29. Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2009;8 (4):309-315.
30. Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1108:121-126.
31. Arenas IA, Armstrong SJ, Xu Y, et al. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension. 2005;46 (1):76-81.
32. Dulai R, Perry M, Twycross-Lewis R, et al. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: A literature review. Semin Arthritis Rheum. 2012;42 (1):1-8.
33. Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009;5 (12):677-684.
34. Murdaca G, Spanò F, Miglino M, et al. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy. 2013;5 (2):113-115.
35. Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008;69 (8):510-512.
36. Ciprandi G, Colombo BM, Murdaca G, et al. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy. 2008;63 (7):945-946.
37. Murdaca G, Spanò F, Puppo F. Selective TNF-α inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12 (2):187-193.
38. Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: A review. Expert Opin Drug Saf. 2015;14 (4):571-582.
39. Bender NK, Heilig CE, Dröll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269-274.
40. Steenholdt C, Svenson M, Bendtzen K, et al. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis. 2012;6 (1):108-111.
41. Atzeni F, Benucci M, Sallì S, et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev. 2013;12 (5):575-579.
42. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm Bowel Dis. 2009;15 (8):1264-1275.
43. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44 (7):774-781.
44. Chaparro M, Guerra I, Muñoz-Linares P, et al. Systematic review: Antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35 (9):971-986.
45. Van der Laken CJ, Voskuyl AE, Roos JC, et al. The formation of infliximab and antiinfliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients. Ned Tijdschr Geneeskd. 2008;152 (30):1672-1677.
46. Kalden JR, Nüsslein HG, Wollenhaupt J, et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol. 2008;26 (5):834-840.
47. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213-222.
48. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
49. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54 (12):3782-3789.
50. Pascual-salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71:1955-1960.
51. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38 (5):502-508.
52. de Vries MK, Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66 (9):1252-1254.
53. Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65 (5):657-661.
54. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120:506-515.
55. Oettgen HC, Martin TR, Wynshaw-Boris A, et al. Active anaphylaxis in IgE-deficient mice. Nature. 1994;370:367-370.
56. Vultaggio A, Matucci A, Parronchi P, et al. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int J Immunopathol Pharmacol. 2008;21:367-374.
57. Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013;43:659-664.
58. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: Aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34 (1):51-58.
59. Sethu S, Govindappa K, Alhaidari M, et al. Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz). 2012;60 (5):331-344.
60. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64 (5):704-707.
61. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48 (5):297-308.
62. Magira E, Lind C, Baldassano R, et al. The HLA DRß13 residue is associated with the development of human anti-chimeric antibody in some Crohn's patients treated with infliximab. Human Immunol. 2009;70 (S1):131.
63. Fasanmade AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: A retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33 (7):946-964.
64. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD-the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38 (10):1188-1197.
65. Pallagi-Kunstár É, Farkas K, Szepes Z, et al. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 2014;20 (17):5031-5035.
66. Bender NK, Heilig CE, Dröll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27 (3):269-274.
67. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet. 2015;385 (Suppl 1):S48.
68. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term followup. Jama. 2011;305 (14):1460-1468.
69. Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164 (2):434-441.
70. van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69 (3):624-625.
71. Kneepkens EL, Wei JC, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74 (2):396-401.
72. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
73. Benucci M, Manfredi M, Saviola G, et al. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-α blocking agents in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:333-336.
74. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289.
75. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003;48:35-45.
76. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71 (11):1914-1915.
77. Sanchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, et al. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol. 2006;24 (5 Suppl 42):S128.
78. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford). 2012;51 (10):1825-1831.
79. Quercia O, Emiliani F, Foschi FG, et al. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011;106 (6):547-548.
80. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-926.
81. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis. Ann Rheum Dis. 2012;71:1914-1915.
82. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947-1955.
83. Kosma M, Avin T, Toplak N, et al. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69 (3):243-248.
84. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72 (1):104-109.
85. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313 (2):578-585.
86. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66 (2):253-256.
87. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. New York (NY): Mount Sinai Medical Center; 2005.
88. Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: unusual to occur after initial dose. Inflamm Bowel Dis. 2012;18: E1592-3.
89. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
90. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
91. Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: Association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134 (10):2503-2509.
92. Murdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10 (12):1703-1710.
93. Murdaca G, Gulli R, Spanò F, et al. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? Drug Dev Res. 2014;75 (Suppl 1):S7-S10.